Recently, there has been a renewed interest in the development of new drugs for the
treatment of leishmaniasis. This has spurred the need for pharmacodynamic markers to …

Pathogen interactions with the host immune response components are critical for
establishing protective immunity and pathological responses against Leishmania parasites …

American Tegumentary Leishmaniasis (ATL) is an endemic disease in Latin America, mainly
caused in Brazil by Leishmania (Viannia) braziliensis. Clinical manifestations vary from mild …

Leishmania (Viannia) braziliensis is the most common etiological agent of cutaneous and
mucocutaneous leishmaniasis (MCL) in Latin America. An interesting aspect of the disease …

The immunopathology associated with Leishmaniasis is a consequence of inflammation.
Upon infection with Leishmania, the type of host-immune response is determinant for the …

American tegumentary leishmaniasis (ATL) samples obtained from the lesions of patients
with typical (n= 25, 29%), atypical (n= 60, 69%) or both (n= 2%) clinical manifestations were …

Leishmaniasis can present as a “spectrum” of clinical outcomes. There is evidence that
these divergent clinical outcomes are attributable to genetic differences in the human host …

BACKGROUND In addition to the limited therapeutic arsenal and the side effects of
antileishmanial agents, drug resistance hinders disease control. In Brazil, Leishmania …

The double stranded RNA (dsRNA) virus Leishmaniavirus (Totiviridae) was first described in
Leishmania guyanensis and L. braziliensis (LRV1), and more recently from L. major and L …

This study aimed at establishing the immunological signature and an algorithm for clinical
management of the different clinical stages of the HTLV-1-infection based on serum …